Latest / Decera Clinical Education Oncology Podcast
Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL
In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:
For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?
What is the optimal therapy for a patient with del(17p) CLL?
When should an anti-CD20 antibody be added to BTK inhibitor therapy for patients with CLL?
What are best…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.